CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Global Assessment for Atopic Dermatitis (vIGA-AD).Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema...
Phase 3
Sevilla, Andalucía, Spain and 196 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Sevilla, Spain and 560 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Sevilla, Spain and 318 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
Sevilla, Andalucía, Spain and 407 other locations
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...
Phase 4
Sevilla, Spain and 106 other locations
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...
Phase 3
Sevilla, Spain and 262 other locations
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
Phase 3
Sevilla, Spain and 308 other locations
Clinical trials
Research sites
Resources
Legal